Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study

Table 4 Characteristics of 160 hepatitis B surface antigen-seropositive cancer patients undergoing cytotoxic chemotherapy n (%)

	Patients developed HBV reactivation (n = 53)	Patients who did not develop HBV reactivation (n = 107)	P value
Sexa			< 0.05
Men	43 (38.4)	69 (61.6)
Women	10 (20.8)	38 (79.2)
Age (yr), median (range)	51.5 (24.8-78.2)	52.9 (27.8-77.9)
Tumor typeb			< 0.05
Lymphomas	10 (55.6)	8 (44.4)
Solid tumor	43 (30.3)	99 (69.7)
Liver cancer	25 (35.7)	45 (64.3)
Others	18 (25.0)	54 (75.0)
ALT levels, median (range) (normal < 58 IU/mL)	69.1 (21.9-116.3)	55.7 (18.2-93.2)
HBeAg statusc			< 0.01
Positive	17 (73.9)	6 (26.1)
Negative	36 (26.3)	101 (73.7)
HBV DNA statusd			< 0.01
Positive	47 (45.2)	57 (54.8)
Negative	6 (10.7)	50 (89.3)
Use of rituximab			< 0.05
Yes	6 (60)	4 (40)
No	47 (31.3)	103 (68.7)
Use of corticosteroids			< 0.05
Yes	8 (61.5)	5 (38.5)
No	45 (30.6)	102 (69.4)
Receiving antiviral therapy			< 0.01
Yes	1 (2.1)	46 (97.9)
No	52 (46.0)	61 (54.0)

^aP = 0.040 (OR: 2.634, 95%CI: 1.046-6.63);

^bP = 0.002 (OR: 5.700, 95%CI: 1.869-17.380);

^cP = 0.000 (OR: 6.064, 95%CI: 2.213-16.621);

^dP = 0.006 (OR: 5.982, 95%CI: 1.689-21.194). OR: Odds ratio; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen.